Medabon is the first product to include a licensed misoprostol preparation formulated for vaginal use. This combined product delivers both components necessary for medical abortion, and was developed to reduce current widespread off-label use of an oral misoprostol product used vaginally.
It is however only licensed for use in pregnancies of gestational age up to 63 days at a dose of 800mcg. As the license is narrow, it is probably more suited to the clinic environment rather than in hospital settings where misoprostol is also used off-label at more advanced stages of gestation, and repeat doses after 800mcg may be required.
The Royal College of Obstetrics and Gynaecology last published guidelines on the care of women requesting induced abortion in 2011 – please see the link below for details.